Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

David A. Hyman, MD, JD, on Inclusive Shared Savings

Cost of Care

The ASCO Post Staff

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Lower Socioeconomic Status Impacts AML Patients’ Ability to Receive Hematopoietic Cell Transplantation

Preclinical Findings Show Ketogenic Diet Enhances CAR T-Cell Function, Improves Tumor Control

Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer

Impact of Prevention and Screening on Mortality From Five Common Cancers

Cancer Risk Associated With Use of Disease-Modifying Antirheumatic Drugs